Skip to content

Why These 2 Overlooked Biotech Stocks Are Deserving Of Attention

“Both of these biotechs deserve a lot more attention than they’ve been receiving,” asserts the author of today’s article in regards to two clinical-stage biotech companies that he proceeds to highlight. For these two overlooked and underappreciated biotech stocks – “a member of the IPO class of 2019 that takes a unique approach to the business of drug development” and one with “a relatively strong candidate for the treatment of Parkinson’s disease that’s meant to provide a lifelong benefit with just one shot” – CLICK HERE.